1. Home
  2. THCH vs CABA Comparison

THCH vs CABA Comparison

Compare THCH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

N/A

Current Price

$1.35

Market Cap

56.7M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.46

Market Cap

462.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
CABA
Founded
2018
2017
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.7M
462.9M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
THCH
CABA
Price
$1.35
$2.46
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
8.3K
4.8M
Earning Date
04-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$2.00
52 Week High
$3.25
$4.23

Technical Indicators

Market Signals
Indicator
THCH
CABA
Relative Strength Index (RSI) 45.46 36.75
Support Level $1.24 $2.02
Resistance Level $2.25 $2.49
Average True Range (ATR) 0.05 0.25
MACD 0.02 -0.09
Stochastic Oscillator 18.75 0.00

Price Performance

Historical Comparison
THCH
CABA

About THCH TH International Limited Ordinary shares

TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: